Alumis Crashed on a Lupus Setback. The Psoriasis Engine Keeps Running.

Alumis stock lost 56% of its value in a single day. The trigger was straightforward: on September 1, the biotech announced that envudeucitinib, its oral TYK2 inhibitor, failed to meet its primary and secondary endpoints in a Phase 2b lupus trial involving 408 patients over 48 weeks. The drug did not demonstrate the level of disease reduction the trial required across the overall population.

For a company that raised $345 million in January — right after two Phase 3 psoriasis trials delivered the headline numbers investors wanted — a clinical failure of any kind is going to hurt. The share price opened at $9.90 after closing at $21.81 the day before and traded as low as $8.76.

The question this creates is what actually broke, because the answer matters more than the headline. The lupus trial was the secondary program. The primary one — plaque psoriasis — sits on the other side of the calendar, on track for a New Drug Application filing with the FDA in the fourth quarter of 2026. And the company's balance sheet has not cracked.

What the lupus failure actually was

The LUMUS trial tested three doses of envudeucitinib against placebo in moderately-to-severely active systemic lupus erythematosus. It missed both its primary endpoint — the BICLA composite score at Week 48 — and its secondary measures. That is a negative result, and it matters.

But the failure has a shape worth understanding. Patients were stratified by interferon gene signature — a biomarker that separates those whose lupus is driven strongly by the interferon pathway (the majority of moderate-to-severe SLE cases) from those where other mechanisms dominate. In the prespecified subgroup with a high interferon signature, envudeucitinib showed robust clinical responses across BICLA, skin lesions, disease activity, and other endpoints. That subgroup was "unexpectedly under-represented" in the trial, which diluted the overall population results.

Pharmacodynamic data confirmed strong, dose-dependent target engagement across the board — the drug was hitting its biological mechanism. Safety remained clean, with no new signals.

Alumis said it plans to engage regulators about a Phase 3 lupus program built around the interferon-high population. It is also exploring cutaneous lupus and Sjögren's disease. None of that is certain, and lupus as a whole has been a graveyard for promising programs. But the failure here is more selective than a blank no.

The asset that actually carries the company

Psoriasis is where Alumis's value lives. In January 2026, the company reported topline results from the ONWARD1 and ONWARD2 Phase 3 trials for moderate-to-severe plaque psoriasis. Both studies met all primary and secondary endpoints. On average, about 65% of patients achieved at least 90% improvement in skin clearance by Week 24, and more than 40% reached complete clearance — PASI 100. Those numbers are competitive with Sotyktu, Bristol Myers Squibb's first-in-class TYK2 inhibitor and the only oral drug in this class currently on the market.

The psoriasis market is estimated at $21.8 billion globally in 2026, with North America holding the dominant share. Sotyktu has been growing but has faced pressure — Bristol Myers recently announced it would sell the drug directly to cash-paying patients at more than 80% below list price, a move that signals competitive anxiety rather than confidence in pricing power. Alumis filed its NDA on a Q4 2026 timeline. If approved, envudeucitinib would be the second oral TYK2 inhibitor for psoriasis, entering a space where the incumbent is still ramping.

The financial bridge

Here is the hard data that separates the stock's pain from the business's:

As of June 30, Alumis held $502.3 million in cash, cash equivalents, and marketable securities. The company carries no short-term debt and has a current ratio of 674%. Management says this cash position funds operations through the fourth quarter of 2027. That is important because it means the company does not need to raise capital to file its NDA, complete post-submission work, or navigate the next 12 to 18 months of regulatory review.

The burn rate tells the story. In Q2 2026, R&D came in at $85.3 million and G&A at $23.4 million, bringing total quarterly operating expenses to roughly $109 million. Trailing twelve-month free cash flow was negative $352 million. The prior year's comparability is distorted by a $188 million non-operating gain from the ACELYRIN merger, so the Q-over-Q trend is the more honest signal: Q1 2026 total expenses were about $100 million, rising to $109 million in Q2 — not a dramatic acceleration. The Phase 3 ONWARD1 and ONWARD2 enrollment and reporting wrapped in January, which took pressure off clinical spending, and that saving was partially offset by the ongoing ONWARD3 extension study.

On a cash-of-$502 million and a run rate around $100 to $110 million per quarter, the runway through late 2027 tracks. The company has time.

The market cap at today's price is $1.23 billion. Enterprise value — market cap minus cash — sits at roughly $727 million. The company generates no commercial revenue; its $1.7 million in Q2 came from a collaboration arrangement with Kaken Pharmaceutical. Every valuation multiple based on current earnings or revenue is meaningless. The real question is whether the NDA, if approved, supports a valuation meaningfully above today's $727 million enterprise value.

That is where you need to think about what the market would assign to a second oral TYK2 inhibitor for psoriasis. Sotyktu's sales trajectory, the competitive landscape of biologics and newer small molecules, and the pricing pressure already visible in this space are all variables that determine whether today's enterprise value is generous, fair, or cheap. None of them have moved because of a lupus Phase 2b result.

What changed and what did not

The lupus disappointment narrows the company's profile from a dual-indication TYK2 story to a psoriasis-first company with lupus optionality. That is a contraction, and it deserves the negative reaction it triggered. A second indication would have expanded the addressable market and reduced single-product risk. Without it, Alumis has one asset, one filing timeline, and one regulatory decision that determines whether this business earns its keep.

But the contraction is real only if you were pricing the lupus upside into the stock already. The market gave Alumis $31.35 per share at its 52-week high, reached in early 2026 after the positive psoriasis Phase 3 data and the $345 million equity raise. The $9.50 price today is a 70% pullback from that peak. Some of that decline predates the lupus result — the stock has been down roughly 64% over the past 20 trading days — which means broader biotech risk-off or position trimming may have done most of the work before today's announcement.

The lupus failure does not change the NDA timeline. It does not change the $502 million cash balance. It does not change the Phase 3 psoriasis data, which remains the strongest evidence base the company has. And it does not change the fact that Sotyktu is still the only approved oral TYK2 inhibitor, with a growing but still-ramping commercial footprint.

The bear case that still stands

The strongest argument against this stock has nothing to do with lupus. It is that Alumis is a binary-outcome company with a single asset heading into regulatory review, burning through cash at roughly $100 million per quarter, and competing in a crowded psoriasis market where biologics already deliver high PASI response rates and where the incumbent oral TYK2 inhibitor — Sotyktu — sets the pricing and physician-adoption bar. Approval is not guaranteed. Even if approved, commercial execution is an entirely separate challenge that a company with no prior commercial experience needs to prove it can handle.

The break condition is clear: if the FDA delays, rejects, or demands additional data beyond the current NDA timeline, the cash runway shortens and dilution becomes the next event. Or if Sotyktu or a competitor establishes such strong first-mover advantage that envudeucitinib cannot carve out meaningful share, the enterprise value at $727 million may prove generous rather than cheap.

The setup

The market is still pricing the old risk profile — a dual-program biotech that just lost half a day's value — while the primary operating setup has not changed. The psoriasis NDA stays on the Q4 2026 timeline. The cash balance provides runway into 2028. The lupus optionality is damaged but not dead, with a prespecified subgroup that showed robust responses and a company planning to discuss a refined Phase 3 approach with regulators.

This is not about excitement. It is about whether a $727 million enterprise value for a company one regulatory decision away from becoming a commercial psoriasis competitor is the right number after a secondary trial setback. The free cash flow is negative $352 million trailing twelve months and will remain negative until at least approval and launch. That is the structural reality of a pre-revenue biotech. The financial bridge does not arrive until an FDA decision and a first product sale — and until then, this is a binary bet on regulatory outcome and a competitive landscape that has not shifted in Alumis's favor since January.

The lupus failure is the headline. It is not the whole story. But the whole story does not require lupus to succeed — and that means the risk here is concentrated in one place: the psoriasis NDA, the Q4 2026 filing, and what happens when the FDA responds.